안과 치료제 시장(2026-2030년)

The global ophthalmology therapeutics market is forecasted to grow by USD 26097.1 mn during 2025-2030, accelerating at a CAGR of 7.1% during the forecast period. The report on the global ophthalmology therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating prevalence of age-related ophthalmic disorders and chronic diseases globally, rapid advancements in sustained-release drug delivery systems and long-acting biologics, increasing strategic collaborations and expanding regulatory approvals across developed regions.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global ophthalmology therapeutics market is segmented as below:

By Type

• Prescription drugs
• OTC drugs

By Product

• Retinal disorder therapeutics
• Glaucoma therapeutics
• Dry eye disease therapeutics
• Eye infections and inflammation therapeutics
• Others

By Drug Class

• Anti-VEGF
• Anti-inflammatory
• Anti-glaucoma
• Anti-infectives
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the integration of autonomous ai and multimodal digital biomarkers in diagnostic screenings as one of the prime reasons driving the global ophthalmology therapeutics market growth during the next few years. Also, paradigm shift toward sustained-release bioerodible implants and long-acting nanotechnology platforms and accelerating market consolidations and strategic cross-border licensing agreements will lead to sizable demand in the market.

The report on the global ophthalmology therapeutics market covers the following areas:

• Global ophthalmology therapeutics market sizing
• Global ophthalmology therapeutics market forecast
• Global ophthalmology therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global ophthalmology therapeutics market vendors that include AbbVie Inc., Alcon Inc., Apellis Pharmaceuticals Inc., Bausch Lomb Corp., Bayer AG, Biogen Inc., EyePoint Pharmaceuticals Inc, F. Hoffmann La Roche Ltd., Genentech Inc., Harrow Inc., Nicox S.A., Novartis AG, Ocugen Inc., Ocular Therapeutix Inc, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc.. Also, the global ophthalmology therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Ophthalmology Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Ophthalmology Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.4 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global ophthalmology therapeutics market
• 6.2 Impact of geopolitical conflicts on global ophthalmology therapeutics market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Prescription drugs - Market size and forecast 2025-2030
• 8.4 OTC drugs - Market size and forecast 2025-2030
• 8.5 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Product

• 9.1 Market segments
• 9.2 Comparison by Product
• 9.3 Retinal disorder therapeutics - Market size and forecast 2025-2030
• 9.4 Glaucoma therapeutics - Market size and forecast 2025-2030
• 9.5 Dry eye disease therapeutics - Market size and forecast 2025-2030
• 9.6 Eye infections and inflammation therapeutics - Market size and forecast 2025-2030
• 9.7 Others - Market size and forecast 2025-2030
• 9.8 Market opportunity by Product
  • Market opportunity by Product ($ million)

10 Market Segmentation by Drug Class

• 10.1 Market segments
• 10.2 Comparison by Drug Class
• 10.3 Anti-VEGF - Market size and forecast 2025-2030
• 10.4 Anti-inflammatory - Market size and forecast 2025-2030
• 10.5 Anti-glaucoma - Market size and forecast 2025-2030
• 10.6 Anti-infectives - Market size and forecast 2025-2030
• 10.7 Others - Market size and forecast 2025-2030
• 10.8 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Escalating prevalence of age-related ophthalmic disorders and chronic diseases globally
  • Rapid advancements in sustained-release drug delivery systems and long-acting biologics
  • Increasing strategic collaborations and expanding regulatory approvals across developed regions
• 13.2 Market challenges
  • Stringent regulatory pipelines and unexpected complete response letters delaying commercialization
  • Economic valuation disparities and complex reimbursement frameworks limiting patient access
  • Clinical compliance and intense treatment burden of invasive ocular modalities
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Integration of autonomous AI and multimodal digital biomarkers in diagnostic screenings
  • Paradigm shift toward sustained-release bioerodible implants and long-acting nanotechnology platforms
  • Accelerating market consolidations and strategic cross-border licensing agreements

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Alcon Inc.
  • Alcon Inc. - Overview
  • Alcon Inc. - Business segments
  • Alcon Inc. - Key offerings
  • Alcon Inc. - Segment focus
  • SWOT
• 15.6 Apellis Pharmaceuticals Inc.
  • Apellis Pharmaceuticals Inc. - Overview
  • Apellis Pharmaceuticals Inc. - Product / Service
  • Apellis Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.7 Bausch Lomb Corp.
  • Bausch Lomb Corp. - Overview
  • Bausch Lomb Corp. - Business segments
  • Bausch Lomb Corp. - Key offerings
  • Bausch Lomb Corp. - Segment focus
  • SWOT
• 15.8 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.9 Biogen Inc.
  • Biogen Inc. - Overview
  • Biogen Inc. - Product / Service
  • Biogen Inc. - Key offerings
  • SWOT
• 15.10 EyePoint Pharmaceuticals Inc
  • EyePoint Pharmaceuticals Inc - Overview
  • EyePoint Pharmaceuticals Inc - Product / Service
  • EyePoint Pharmaceuticals Inc - Key offerings
  • SWOT
• 15.11 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.12 Genentech Inc.
  • Genentech Inc. - Overview
  • Genentech Inc. - Product / Service
  • Genentech Inc. - Key offerings
  • SWOT
• 15.13 Harrow Inc.
  • Harrow Inc. - Overview
  • Harrow Inc. - Product / Service
  • Harrow Inc. - Key offerings
  • SWOT
• 15.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.15 Ocugen Inc.
  • Ocugen Inc. - Overview
  • Ocugen Inc. - Product / Service
  • Ocugen Inc. - Key offerings
  • SWOT
• 15.16 Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc. - Overview
  • Regeneron Pharmaceuticals Inc. - Product / Service
  • Regeneron Pharmaceuticals Inc. - Key news
  • Regeneron Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.17 Santen Pharmaceutical Co. Ltd.
  • Santen Pharmaceutical Co. Ltd. - Overview
  • Santen Pharmaceutical Co. Ltd. - Product / Service
  • Santen Pharmaceutical Co. Ltd. - Key offerings
  • SWOT
• 15.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations